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toring was defined as receipt of1 serum ferritin test after 10th unit. ICT-eligibility
was defined as 2 serum ferritin tests 1,000 g/L or 20 units transfused. ICT
treatment was defined as 1 prescription/administration for deferasirox or defer-
oxamine. Kaplan-Meier and Cox proportional hazards regression methods were
used to compare overall survival. RESULTS: A total of 163 patients were included;
58.3% and 30.1% received20 and30 RBC units, respectively. A total of 50.3% had
leukemia and 20.2% had myelodysplastic syndrome as the underlying disease. A
total of 44.8%, 53.7% and 67.3% of patients receiving 10, 20 and 30 RBC units,
respectively, were monitored for TIO. Compared to unmonitored patients, TIO-
monitored patients had significantly longer median OS (16.13 vs. 2.30 months;
log-rank p-value0.001) even after confounder adjustment (hazards ratio 0.271;
p-value0.001). Among 99 ICT-eligible patients, 9% received ICT; 8 (88.9%) received
deferasirox. Median OS for ICT-treated patients and untreated patients was 9.48
and 7.16 months, respectively (log-rank p-value0.593). CONCLUSIONS: To con-
clude, TIO monitoring after 10 RBC units may be associated with survival benefits,
but 50% of patients receiving 10 transfusions were monitored for TIO. Clinical
benefits of chelating cancer patients have not been established and additional
studies are necessary to ascertain the impact of TIO and chelation utility among
cancer patients.
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OBJECTIVES: Acquired hemophilia (AH) is a rare disorder (1 per 1.3 million) char-
acterized by auto-antibodies to factor VIII. AH is characterized by life-threatening
bleeding and high mortality. Recombinant factor VIIa (rFVIIa) received FDA ap-
proval for treatment of AH in 2006. As part of the post-approval commitment, Novo
Nordisk agreed to use a society-owned research registry to monitor treatment of
AH bleeding episodes. This required IRB approval and informed consent. For sites
with few patients and/or limited research staff, the registry was not a feasible
option METHODS: An alternative web-based, IRB-exempt reporting method, Ac-
quired Hemophilia Surveillance (AHS, www.novosevensurveillance.com), was es-
tablished to collect data on rFVIIa use in AH and associated adverse events under
the HIPAA safety surveillance waiver. RESULTS: From April 2008-January 2011, 32
reporters submitted 80 case reports (32 male/48 female). The mean age was 65
years (range 16-97). Common associated conditions were autoimmune disorders
(32 patients), malignancy (6 patients) and post-partum state (5 patients). On aver-
age, 5 discrete bleeding events per patient (range 0-100) were reported; 75 case
reports described bleeding as spontaneous (88%), surgical (16%), and/or related to a
procedure (15%). No bypassing agent was reported to have been used in 17 (21%).
rFVIIa was used in 50 (63%), the majority of which were first-line (39, 78%). AH was
reported to have been “resolved” in 44 (55%), “not resolved” in 19 (24%), and “un-
sure” in 16 (20%); mean(median) time to resolution was 7.2(2) months (range 1-52).
There were no reported deaths. None of the 50 rFVIIa-treated cases suffered an
adverse or thrombotic event (AE). CONCLUSIONS: AHS provides an innovative ap-
proach for hemophilia treatment centers and hematology/oncology practices to
capture basic safety surveillance data for patients with Acquired Hemophilia. The
AHSproject provides additional information aboutAH treatment, and reaffirms the
safety of rFVIIa and the low rate of thrombotic complications.
Systemic Disorders/Conditions – Cost Studies
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OBJECTIVES: Compare costs of privately-insured oxymorphone extended-release
tablet (“oxymorphone”) users with those of oxycodone controlled-release tablet
(“oxycodone”) users, from an employer’s perspective. METHODS: Patients, ages
18, with 1 claim for oxymorphone/oxycodone during Q2:2006-Q4:2009 were
identified in de-identified private payer claims data and observed from the first
such claim (“index date”) until the earliest of: use of comparator drug; end of
continuous eligibility; or 12 months (“study period”). Continuous eligibility was
required throughout a 6-month baseline period and1month after the index date.
Patients with claims for any formulation (extended-release or otherwise) of the
comparator drug during the first 30 days of the study periodwere excluded, aswere
patients pregnant during the baseline/study periods. Study period risk-adjusted
costs were estimated per patient-month using generalized estimating equations
controlling for baseline demographics, resource use, and costs. Medical/drug (di-
rect) costs paid by private insurers were reported for patients ages 18-64 (N 8,354)
and 65 (N  3,515) as well as subsets of each without cancer during the baseline/
study periods (N  7,090 and N  2,444, respectively). Medically-related absentee-
ism and disability (indirect) costs were reported for all employees, ages 18-64, (N
1,313) and employeeswithout cancer (N 1,146). Bias-corrected bootstrappingwas
used to compare third-party payer costs. RESULTS: Oxymorphone users, ages 18-
64, had lower drug costs ($693 vs. $763, p0.0035) and similar medical costs ($1,875
vs. $1,976, p0.3570) per patient-month compared with oxycodone users. Indirect
costs were not different ($662 vs. $670, p0.9370). Oxymorphone users, ages 65,
had similar Medicare supplemental drug costs ($533 vs. $588, p0.0840) and signif-
icantly lower medical costs ($459 vs. $747, p0.0001). Results were comparable for
the subsets without cancer. CONCLUSIONS: After controlling for baseline charac-
teristics, real-world evidence suggests that, from an employer’s perspective, oxy-
morphone users may incur lower monthly direct costs than oxycodone users.
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OBJECTIVES: The objective of this study was to compare the effectiveness and
costs of TachoSil® carrier-bound collagen sponges versus Tissucol® fibrin glue in
patients undergoing liver surgery in current medical practice.METHODS: A retro-
spective observational cohort study was carried out including 244 patients (128 in
TachoSil® group and 116 in Tissucol® group) that underwent a liver surgery a
university hospital. Data on demographics, medical background, effectiveness, re-
source consumption and complicationswere obtained by reviewing patients=med-
ical records. Unit costs were obtained from financial hospital records and drug
costs from the Spanish health authorities. Collection of patient data took place
from definitive surgery until hospital discharge using a hospital=s perspective.
Variables collected to estimate costs and effectiveness were haemostatic drugs,
surgical time, drainage, blood transfusions and hospitalisation days. Research out-
comes were presented as the differences in effectiveness measures and costs for
the collected variables using statistical analysis (p0.05).RESULTS:WithTachoSil®
significantly less patients required a drainage (12.5% vs. 52.6%, p0.001) and pa-
tients were hospitalized for a minor number of days (median 6 vs. 8 days,
p0.00013). No statistical differences between both groups were observed in the
rest of the effectiveness data pre- and postoperative. The TachoSil® group showed
significant lower mean costs with respect to haemostatic drugs (mean [SD] euro,
974€ [787€] vs. 987€ [384€], p0.03) and drainage (3€ [7€] vs. 12€ [11€], p0.00). No
significant differences in other costs between both treatments were reported.
CONCLUSIONS: TachoSil® showed to reduce drainage and hospitalisation days.
However no significant lower total costs for the TachoSil® group (10,212€ [8,197€])
vs. the Tissucol® group (10,224€ [7,394€]) could be demonstrated.
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OBJECTIVES: Spaepen et al. (the Oncologist 2008;13:596–607) published a cost-
analysis comparing darbepoetin alfa (DARB), epoetin alfa (EPO-A) and epoetin beta
(EPO-B) in the treatment of chemotherapy-induced anemia, using propensity score
matching. The study was performed using the IMS Hospital Disease Database, a
longitudinal database unique to Belgium containing individual patient/admission-
level data on diagnoses, procedures, and pharmaceuticals. Given the limited avail-
ability of other databases reporting the same level of information in other Euro-
pean countries, the objectives of this study were to assess the applicability of the
Belgian analysis, and to estimate differences in costs between ESAs in Austria,
Italy, Portugal, and Spain. METHODS: To adapt the analysis, costs were replaced
with country-specific costs and discrepancies in epidemiology and treatment pat-
terns were examined. Adjusting for country discrepancies, costs were analyzed
using a mixed-effects model stratifying for propensity score quintiles as in Spa-
epen 2008. Sources included Eurostat, national cancer registries, IMS sales data,
and reimbursement and treatment guidelines for procedures and drugs. RESULTS:
All populations were comparable to Belgium in terms of age, gender, ESA use, and
blood transfusions. Adjusting for chemotherapy use and tumor-specific cancer
incidence, total costs (Euro, 2010)withDARBwere 22-26% lower compared to EPO-A
and 20-35% lower compared to EPO-B. Anemia-related costs were lowest for DARB
€2,585154, EPO-A €3,10299, EPO-B €2,969166 in Austria; DARB €3,144211,
EPO-A €5,049119, EPO-B €3,656230 in Italy; DARB €2,153117, EPO-A €2,44663,
EPO-B €2,654124 in Portugal; and DARB €2,378143, EPO-A €3,34975, EPO-B
€2,857153 in Spain. CONCLUSIONS: Total and anemia-related costs were lowest
in patients receiving DARB compared to EPO-A or EPO-B in all countries. Although
it was not possible to account for all differences among countries, the findings are
in line with those from the Belgian analysis, and demonstrate the feasibility of
adapting such data to other settings accounting for patient characteristics and
treatment costs.
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